NEUFELD, Austria, Feb. 25, 2025 /PRNewswire/ -- Sanochemia Pharmazeutika today announced positive headline results of the pivotal phase III study PROSTAPROGRESS on Ferumoxtran (EudraCT 2018-004310-18), performed by SPL Medical B.V. (Nijmegen, The Netherlands). The multicentric prospective...
Read More Details
Finally We wish PressBee provided you with enough information of ( Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study )
Also on site :
- Diddy Trial Recap: Kid Cudi Testifies About Home Break-In and Porsche Molotov Cocktail Explosion
- Universal's Long-Awaited New Theme Park Finally Opens
- Inside Mercedes-Benz’s plans to create a new HQ with hundreds of jobs in Atlanta